Double-Expressor Lymphoma — Trials

Double-Expressor Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

11 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 7
Recruiting: 3
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01742988	Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma	completed	Phase 1	106	Curis, Inc.INDUSTRY	1	May 6, 2021	clinicaltrials

Data updated 22 days agoSource updated May 6, 2021source: clinicaltrials